Antonia Kalykaki
Overview
Explore the profile of Antonia Kalykaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
269
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papadaki C, Manolakou S, Lagoudaki E, Pontikakis S, Ierodiakonou D, Vogiatzoglou K, et al.
Cancers (Basel)
. 2020 Apr;
12(4).
PMID: 32326107
CD44, a surface marker for cancer stem cells, interacts with PKM2, a key regulator of aerobic glycolysis, and enhances the glycolytic phenotype of cancer cells leading to antioxidant protection and...
2.
Apostolou P, Fostira F, Kouroussis C, Kalfakakou D, Delimitsou A, Agelaki S, et al.
Int J Cancer
. 2020 Feb;
147(5):1334-1342.
PMID: 32022259
Germline BRCA1 and BRCA2 loss-of-function variants have been linked to increased breast and ovarian cancer risk, with more than 5,000 distinct pathogenic variants being reported worldwide. Among individuals of Greek...
3.
Agelaki S, Kalykaki A, Markomanolaki H, Papadaki M, Kallergi G, Hatzidaki D, et al.
PLoS One
. 2015 Jun;
10(6):e0123683.
PMID: 26083256
Background: To evaluate the efficacy of lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, in therapy-resistant HER2-positive CTCs in metastatic breast cancer (MBC). Patients And Methods: Patients with MBC...
4.
Koinis F, Polyzos A, Christopoulou A, Zafeiriou Z, Emmanouilidis C, Papadimitraki E, et al.
Cancer Chemother Pharmacol
. 2014 Feb;
73(4):819-25.
PMID: 24531559
Purpose: To evaluate the safety and antitumor activity of docetaxel (DOC) and pegylated liposomal doxorubicin (PLD) combination in patients with platinum- and taxane-sensitive ovarian cancer. Patients And Methods: Twenty-three patients...
5.
Kalykaki A, Agelaki S, Kallergi G, Xyrafas A, Mavroudis D, Georgoulias V
Cancer Chemother Pharmacol
. 2014 Feb;
73(4):685-93.
PMID: 24493157
Purpose: The purpose of the study is to evaluate the effect of gefitinib, an anti-EGFR TKI on circulating tumor cells (CTCs) in patients with metastatic breast cancer (MBC). Methods: Seventeen...
6.
Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K, et al.
Breast Cancer Res
. 2011 Jun;
13(3):R60.
PMID: 21663668
Background: The detection of cytokeratin-19 (CK-19) mRNA-positive circulating tumor cells (CTC) before and/or after adjuvant chemotherapy in patients with operable breast cancer is associated with poor clinical outcome. Reliable prognostic...
7.
Kotsakis A, Agelaki S, Vardakis N, Stathopoulos G, Vamvakas L, Kalykaki A, et al.
Cancer Chemother Pharmacol
. 2010 Nov;
68(2):415-22.
PMID: 21069335
A phase I study was conducted to determine the maximum tolerated doses (MTD) and the dose-limiting toxicities (DLT) of pemetrexed and docetaxel in patients with advanced unresectable or metastatic non-small-cell...
8.
Kotsakis A, Hatzidaki D, Vamvakas L, Vardakis N, Kalykaki A, Bozionelou V, et al.
Anticancer Res
. 2010 Nov;
30(10):4335-42.
PMID: 21036760
Background: Platinum-based chemotherapy represents the standard of care for advanced non-small cell lung cancer (NSCLC) while non-platinum-based regimens are frequently administered in patients with relapse. A retrospective analysis of the...
9.
Polyzos A, Kalbakis K, Kentepozidis N, Giassas S, Kalykaki A, Vardakis N, et al.
Cancer Chemother Pharmacol
. 2010 Oct;
68(1):217-23.
PMID: 20922389
Background: Weekly paclitaxel (P) in combination with bevacizumab (B) is an effective regimen as initial treatment of metastatic breast cancer (MBC). We investigated in a phase II study the activity...
10.
Karachaliou N, Polyzos A, Kentepozidis N, Kakolyris S, Ziras N, Vardakis N, et al.
Oncology
. 2010 Aug;
78(5-6):356-60.
PMID: 20798557
Purpose: To evaluate the efficacy and tolerability of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11) as first-line treatment of advanced biliary tract cancer. Patients And Methods: Patients with histologically confirmed...